Cellectar Biosciences, Inc. — Q3 2018 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2018. Filed November 13, 2018. Cellectar is a clinical-stage biopharmaceutical company developing cancer therapies using its phospholipid drug conjugate (PDC) platform. It reported no revenue in the presented periods and expects continuing operating losses.
Financial performance and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Research and development expense | $2.00 million | $2.33 million | $5.80 million | $6.37 million |
| General and administrative expense | $1.09 million | $1.15 million | $3.65 million | $3.15 million |
| Total costs and operating loss | $3.09 million | $3.48 million | $9.45 million | $9.51 million |
| Net loss | $3.01 million | $3.47 million | $9.41 million | $9.48 million |
| Net loss attributable to common stockholders | $5.26 million | $3.47 million | $11.65 million | $9.48 million |
| Basic and diluted loss per share | $1.65 | $2.58 | $5.29 | $7.30 |
Common-stockholder loss included a $2.24 million deemed dividend related to the beneficial conversion feature of Series C preferred stock; it did not increase total stockholders’ equity. No profit or operating margin was reported; the company had no revenue.
- Cash and cash equivalents: $16.37 million at September 30, 2018, versus $10.01 million at December 31, 2017; restricted cash was $55,000.
- Cash flow, nine months: $8.70 million used in operations, compared with $8.19 million in 2017. Investing activities provided $44,000; financing provided $15.02 million. Net cash, cash equivalents and restricted cash increased $6.37 million.
- Liquidity: Current assets were $17.11 million and current liabilities $2.66 million. Management said cash should fund operations into the first quarter of 2020; the notes also state liquidity is sufficient for 12 months from filing. This remains dependent on spending, clinical progress and access to financing.
- Debt and equity: Total liabilities were $2.66 million; capital lease obligations were about $3,000 current, with no long-term liabilities. Stockholders’ equity was $16.88 million and accumulated deficit $93.76 million.
Changes versus comparable periods
- Q3 total costs declined 11% year over year and net loss narrowed about 13%. R&D fell 14%, principally from increased NCI contract reimbursements and lower manufacturing costs during the CLR 131 supply interruption. G&A fell 5%, largely due to lower legal fees.
- Nine-month total costs declined less than 1%, while net loss improved less than 1%. R&D decreased 9%, mainly from lower general R&D expense and increased NCI reimbursements; G&A increased 16%, reflecting purchased services and personnel costs.
- Headcount fell from 15 at December 31, 2017 to 7 at September 30, 2018. The company was shifting to outsourced manufacturing and other external collaborators.
- Cash increased following the July 2018 public offering, which generated approximately $15.03 million net proceeds. The offering included common shares, Series C preferred stock convertible into common shares, and Series E warrants.
Outlook, developments and risks
- CLR 131 supply and trial risk: CPDC, the company’s sole supplier, was subject to an FDA Import Alert, interrupting supply in August 2018. On November 8, 2018, after quarter-end, the FDA authorized shipments to sites in ongoing hematology trials; Cellectar planned to resume enrollment there. Authorization for shipments for the pediatric Phase 1 study remained pending, and enrollment was delayed. The company could not estimate the full impact or duration.
- Pipeline: CLR 131 was being studied in Phase 2 for relapsed/refractory multiple myeloma and other B-cell malignancies, and in Phase 1 for multiple myeloma. Management described interim response signals in DLBCL and Waldenstrom macroglobulinemia and planned a sixth Phase 1 dose cohort. These are preliminary clinical observations, not proof of efficacy. A pediatric Phase 1 study and a head-and-neck cancer study were planned; the latter was anticipated to start in the second half of 2019.
- Other programs: The company reported five active PDC collaborations and described CLR 1900 as an early preclinical program. Development, regulatory and commercialization outcomes remain uncertain.
- Operating outlook: Management expects ongoing operating losses and identifies the need for additional financing, reliance on key personnel and suppliers, competition, and successful product development and regulatory approval as principal risks.
- Unusual items and commitments: R&D expense included an approximately $267,000 charge related to decommissioning the former manufacturing facility. The company recorded an approximately $267,000 liability for remaining Madison lease obligations. A new 64-month lease was expected to commence after tenant improvements; aggregate rent was approximately $783,000 after abatements, plus operating expenses and taxes.
- Potential dilution: At September 30, 2018, 5.32 million warrants were outstanding, including 4.14 million Series E warrants exercisable at $4.00 per share through July 2023. A 1-for-10 reverse stock split took effect July 16, 2018. The filing reported 4.27 million common shares outstanding at September 30 and 4.76 million as of November 9.
- Controls and legal matters: Management reported disclosure controls were effective and no material change in internal control during the quarter. The company reported no legal proceedings and did not expect ordinary-course disputes to materially affect its financial statements.
Investor verification points
- Confirm the timing and consistency of CLR 131 supply, FDA shipment permissions, and trial enrollment resumption—especially for the pediatric study.
- Track clinical-trial progress, data maturity, safety, and whether reported response signals are confirmed in larger patient groups.
- Assess the cash runway against operating burn and the stated first-quarter 2020 funding horizon, including the potential need for further capital.
- Review dilution exposure from warrants, preferred-stock conversion, and subsequent share issuances.
- Monitor outsourced manufacturing and collaborator reliability, lease obligations, and the financial impact of the company’s transition away from internal manufacturing.